RUDN University veterinarians tested a new drug against pneumonia in calves

February 10, 2021

Respiratory tract diseases in young animals of the cattle are a big issue for world agriculture and food safety because a bacterium that causes them is resistant to most antibiotics. A team of veterinarians from RUDN University developed and tested a complex preparation called gentaminoseleferon that could help treat respiratory infection in calves. The results of the study were published in the Veterinary World journal.

Bacteria of the genus Mycoplasma cause many infectious diseases in animals, including atypical pneumonia, other respiratory tract conditions, reproductive pathologies, arthritis, keratoconjunctivitis, mastitis, and so on. The genus includes about 200 species of bacteria, and all of them are dangerous for animals. While the action of many antibiotics is focused on the destruction of bacterial cell walls, Mycoplasma cells don't have it which makes Mycoplasma diseases difficult to treat. A team of veterinarians from RUDN University tested a new drug against Mycoplasma dispar that often causes pneumonia in calves.

"Respiratory diseases of young cattle cause economic damage on a global scale. They are treated with complex preparations that support natural body resistance, normalize metabolism, and have an anti-inflammatory effect. Our goal was to study the therapeutic efficiency of gentaminoseleferon against respiratory tract diseases in calves, in particular the Mycoplasma dispar infection," said Mohammad Abed Alhussen and Hamdan Naef, postgraduate students at the Center for Innovative Veterinary Medicine, RUDN University.

The team conducted a pilot study of the drug on 15 calves that were divided into three groups: the first one was a control group with healthy animals and the second and the third contained calves with early clinical signs of the respiratory infection. Each calf from the second group was intramuscularly injected with 5 to 10 ml sulfetrisan (a drug based on the antibiotics sulfadimethoxine, erythromycin, and trimethoprim that is traditionally used to treat this disease) for seven days. The third group received gentaminoseleferon injections in the dose of 1 ml per 10 kg of mass for the same time. The healthy calves from group one did not receive any treatment. The team took blood samples from all animals 10 days before and after the treatment.

As a result of treatment, the biochemical properties and plasma parameters of the blood of infected calves returned to normal. Moreover, the third group experienced an additional positive effect: the protein content in their blood plasma increased by 2.2% compared to the second group, the level of vitamin A grew by 13.5%, E by 11.9%, C by 15.1%, iron by 9.3%, and zink by 4.1%. While in the course of the illness the bodies of the calves lacked these vitamins and microelements, after the treatment they returned to normal levels.

"These results indicate a prominent decrease of inflammatory processes in the respiratory tract along with active recovery of metabolism, thus confirming the therapeutic efficiency of gentaminoseleferon," added Mohammad Abed Alhussen and Hamdan Naef from RUDN University.
-end-


RUDN University

Related Antibiotics Articles from Brightsurf:

Insights in the search for new antibiotics
A collaborative research team from the University of Oklahoma, the Memorial Sloan Kettering Cancer Center and Merck & Co. published an opinion article in the journal, Nature Chemical Biology, that addresses the gap in the discovery of new antibiotics.

New tricks for old antibiotics
The study published in the journal Immunity reveals that tetracyclines (broad spectre antibiotics), by partially inhibiting cell mitochondria activity, induce a compensatory response on the organism that decreases tissue damage caused during infection.

Benefits, risks seen with antibiotics-first for appendicitis
Antibiotics are a good choice for some patients with appendicitis but not all, according to study results published today in the New England Journal of Medicine.

How antibiotics interact
Understanding bottleneck effects in the translation of bacterial proteins can lead to a more effective combination of antibiotics / study in 'Nature Communications'

Are antivitamins the new antibiotics?
Antibiotics are among the most important discoveries of modern medicine and have saved millions of lives since the discovery of penicillin almost 100 years ago.

Hygiene reduces the need for antibiotics by up to 30%
A new paper published in the American Journal of Infection Control (AJIC), finds improved everyday hygiene practices, such as hand-washing, reduces the risk of common infections by up to 50%, reducing the need for antibiotics, by up to 30%.

Antibiotics: City dwellers and children take the most
City dwellers take more antibiotics than people in rural areas; children and the elderly use them more often than middle-aged people; the use of antibiotics decreases as education increases, but only in rich countries: These are three of the more striking trends identified by researchers of the NRW Forschungskolleg ''One Health and Urban Transformation'' at the University of Bonn.

Metals could be the link to new antibiotics
Compounds containing metals could hold the key to the next generation of antibiotics to combat the growing threat of global antibiotic resistance.

Antibiotics from the sea
The team led by Prof. Christian Jogler of Friedrich Schiller University, Jena, has succeeded in cultivating several dozen marine bacteria in the laboratory -- bacteria that had previously been paid little attention.

Antibiotics not necessary for most toothaches, according to new ADA guideline
The American Dental Association (ADA) announced today a new guideline indicating that in most cases, antibiotics are not recommended for toothaches.

Read More: Antibiotics News and Antibiotics Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.